Related Experiment Video

Updated: Jul 23, 2026

The Double-H Maze: A Robust Behavioral Test for Learning and Memory in Rodents
09:01

The Double-H Maze: A Robust Behavioral Test for Learning and Memory in Rodents

Published on: July 8, 2015

Facilitation of memory performance by a novel muscarinic agonist in young and old rats

A C Ruske1, K G White

  • 1University of Otago, Department of Psychology, Dunedin, New Zealand.

Pharmacology, Biochemistry, and Behavior
|August 26, 1999
PubMed

Insights

AF150(S), a muscarinic receptor agonist, improved memory performance in young and old rats. This cognitive enhancement was observed as a reduced rate of forgetting in a memory task.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Cognitive Science

Background:

  • Muscarinic acetylcholine receptors play a crucial role in cognitive functions.
  • Age-related cognitive decline is a significant concern, necessitating therapeutic interventions.
  • Partial M1 muscarinic receptor agonists are being investigated for their potential cognitive-enhancing effects.

Purpose of the Study:

  • To evaluate the efficacy of AF150(S), a novel partial M1 muscarinic receptor agonist, in improving cognitive performance.
  • To assess the effects of AF150(S) on a delayed matching-to-position task in both young and aged rats.

Main Methods:

  • Rats (young and old) were administered intraperitoneal injections of AF150(S) at doses of 0, 1, and 4 mg/kg.
  • Performance was assessed using a delayed matching-to-position task, a measure of working memory and attention.
  • Statistical analysis involved fitting exponential functions to discriminability measures to quantify changes in performance.

Main Results:

  • AF150(S) significantly improved matching accuracy in both young and old rats across tested doses.
  • The observed cognitive enhancement was characterized by a reduction in the rate of forgetting, indicating improved memory retention.
  • Dose-dependent effects were observed, suggesting a specific pharmacological action.

Conclusions:

  • AF150(S) demonstrates significant cognitive-enhancing properties, particularly in improving memory performance and reducing forgetting.
  • These findings suggest that AF150(S) holds promise as a potential therapeutic agent for cognitive dysfunction.
  • Further research into M1 muscarinic receptor agonists like AF150(S) is warranted for treating memory impairments.

More Related Videos

Novel Object Recognition Test for the Investigation of Learning and Memory in Mice08:52

Novel Object Recognition Test for the Investigation of Learning and Memory in Mice

Published on: August 30, 2017

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Related Concept Videos

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...